ERVW-1 and infection: In the efficacy trial conducted in Thailand, priming with a recombinant canarypox vector vaccine (ALVAC-HIV) and boosting with recombinant gp120 subunit vaccine (AIDSVAX B/E) induced ADCC activity that was associated with a reduced risk of infection in a subgroup of individuals with low serum IgA Env-specific antibodies [22,35].